Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial
Authors:
Open Access
- 5 October 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (19) , 2464-2471
Abstract
Background: An evidence gap still exists regarding the efficacy and safety of tegoprazan in patients with erosive esophagitis (EE) in China. This study aimed to verify the efficacy and safety of tegoprazan vs . esomeprazole in patients with EE in China. Methods: This study was a multicenter, randomized, double-blind, parallel, active-controlled, non-inferiority phase III trial of patients with EE randomized 1:1 to tegoprazan 50 mg/day vs . esomeprazole 40 mg/day. This study was conducted in 32 sites between October 24, 2018 and October 18, 2019. The primary endpoint was the cumulative endoscopic healing rate at week 8. The secondary endpoint included endoscopic healing rate at week 4, changes in the reflux disease questionnaire (RDQ) and gastroesophageal reflux disease health-related quality of life (GERD-HRQL) scores, and symptom improvement. Results: A total of 261 patients were randomized: 132 to the tegoprazan group and 129 to the esomeprazole group. The cumulative endoscopic healing rate at 8 weeks in the tegoprazan group was non-inferior to that of the esomeprazole group (91.1% vs . 92.8%, difference: −1.7%, 95% confidence interval [CI]: −8.5%, 5.0%, P = 0.008). There were no statistically significant differences in the changes in RDQ (total, severity, and frequency) and GERD-HRQL scores between the two groups (all P >0.05). The percentages of days without symptoms, including daytime and nighttime symptoms based on patients’ diaries, were similar between the two groups (all P >0.05). In the tegoprazan and esomeprazole groups, 71.5% (93/130) and 61.7% (79/128) of the participants reported adverse events (AEs), 2.3% and 0 experienced serious AEs, while 70.0% and 60.2% had treatment-emergent AEs, respectively. Conclusion: Tegoprazan 50 mg/day demonstrated non-inferior efficacy in healing EE, symptom improvement, and quality of life, and it has similar tolerability compared with esomeprazole 40 mg/day. Trial Registration: ClinicalTrials.gov, NCT03615677.Keywords
This publication has 46 references indexed in Scilit:
- Gastro-oesophageal reflux diseaseNature Reviews Disease Primers, 2021
- Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysisScientific Reports, 2020
- The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Gastroenterology & Hepatology, 2020
- Gastroesophageal Reflux DiseasePrimary Care: Clinics in Office Practice, 2017
- Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowthJournal of Gastroenterology, 2017
- How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based ApproachCurrent Gastroenterology Reports, 2016
- The Los Angeles Classification of Gastroesophageal Reflux DiseaseVideo Journal and Encyclopedia of GI Endoscopy, 2013
- Guidelines for the Diagnosis and Management of Gastroesophageal Reflux DiseaseAmerican Journal of Gastroenterology, 2013
- The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infectionAmerican Journal of Gastroenterology, 2000
- Helicobacter pylori and gastro-oesophageal reflux disease — A prospective studyIrish Journal of Medical Science (1971 -), 1994